Working… Menu

Ivermectin as a Novel Therapy in COVID-19 Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04403555
Recruitment Status : Recruiting
First Posted : May 27, 2020
Last Update Posted : January 20, 2021
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
Efficacy of Ivermectin in COVID-19 treatment

Condition or disease Intervention/treatment Phase
COVID Drug: Ivermectin Phase 2 Phase 3

Detailed Description:
Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy of Ivermectin in COVID-19 Treatment
Actual Study Start Date : June 1, 2020
Estimated Primary Completion Date : December 1, 2030
Estimated Study Completion Date : December 3, 2030

Resource links provided by the National Library of Medicine

Drug Information available for: Ivermectin

Arm Intervention/treatment
Experimental: Ivermectin
Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
Drug: Ivermectin
Ivermectin treatment
Other Name: iverzine, ivermectin

No Intervention: Standard of care
Standard of care treatment

Primary Outcome Measures :
  1. The number of patients with improvement or mortality [ Time Frame: 1 month ]
    The number of patients with improvement or mortality

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • COVID 19 positive patients

Exclusion Criteria:

  • Allergy or contraindication to the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04403555

Layout table for location contacts
Contact: Sherief Abd-Elsalam, ass. prof. 00201147773440

Layout table for location information
Sherief Abd-Elsalam Recruiting
Tanta, Egypt
Contact: Sherief Abd-Elsalam, Ass. Prof.    00201009221243   
Sponsors and Collaborators
Tanta University
Layout table for investigator information
Principal Investigator: sherief Abd-Elsalam, Ass. Prof. ass. Prof. Tropical Medicine
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University Identifier: NCT04403555    
Other Study ID Numbers: tanta covid treatment
First Posted: May 27, 2020    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antiparasitic Agents
Anti-Infective Agents